Device-Drug Combination Products: Regulatory Boundaries and Filing Pathways

1. Key takeaways

Combination products in Malaysia are not administered by a single authority. Drug-device combinations are allocated according to the lead agency principle: where the device aspect dominates, the MDA takes the file; where the drug aspect dominates, the NPRA (National Pharmaceutical Regulatory Agency) takes it; and where the dominant aspect cannot be determined, both agencies are notified in parallel.

The allocation is not a matter of preference. It determines which application form is used, which reporting channel applies, and which set of timelines governs an adverse event. Because the answer can differ between the registration stage and the reporting stage, the analysis has to be recorded rather than assumed.

• Lead agency principle: device-dominant to the MDA, drug-dominant to the NPRA, undetermined to both in parallel.
• Examples: bone cement (MDA); drug-eluting stent (MDA lead, drug issues to the NPRA); metered dose inhaler (NPRA); prefilled insulin pen (NPRA); peritoneal dialysis fluid (device issues to the MDA).
• Filing route: determine the lead agency, then file on that agency’s pathway, with an ancillary dossier to the supporting agency for the cross-attribute parts.
• Reporting: dual track where two agencies are involved; MDA-side reports do not go through MeDCReSt.
• MDA channel: MPR form PART 1 and PART 2 by email to mpr@mda.gov.my.
• Local timelines: failure or labelling defect 30 days; death or serious deterioration 10 days; serious public health threat 48 hours.
• Foreign timelines: major safety issue no later than 3 calendar days; foreign withdrawal or suspension of registration 24 hours.
• Fee: a drug-containing device carries a registration fee of RM5,000 with an application fee of RM750 under the Fifth Schedule, which differs from the pure device C and D bands.

2. Legal basis

The governing document is the MDA Guideline for Drug-Medical Device and Medical Device-Drug Combination Products, in its fifth edition, which contains the lead agency table and the reporting timeline table. The Fifth Schedule to the MDR 2012 sets the registration fee for a drug-containing device. The MDA Vigilance Unit page carries the email channel used for combination product reports. Because a combination product sits across two regulatory regimes, the guideline is the instrument that resolves which regime applies to which question.

The comparison with the Chinese framework is useful up to a point. China also reviews drug-device combinations according to their attributes, but the agency division differs, so the analogy should be used to frame the question rather than to supply the answer. In Malaysia the practical task is to establish, for each component and each claim, which agency’s expertise is engaged.

3. Expert insights

Insight 1: the lead agency can differ by question, not only by product.

The drug-eluting stent illustrates the point. The product is MDA-led, but drug issues go to the NPRA. That means a single device can generate two conversations with two agencies depending on what the question is about. Companies that assign one agency to the product and stop there will route a drug-related query to the wrong body, and the error is only discovered when a response does not arrive. The correct unit of analysis is the issue, not the catalogue entry.

Insight 2: the ancillary dossier is where timelines are lost.

Filing on the lead agency pathway does not dispose of the cross-attribute parts: supplementary material still has to go to the supporting agency as an ancillary dossier. The two streams are governed by different reviewers with different questions, and a submission that is complete for one is not automatically complete for the other. Planning the dossier as a single package with two destinations, rather than as one filing plus an afterthought, is the difference between a predictable review and a series of deficiency rounds.

Insight 3: foreign event timelines are much shorter than local ones.

The guideline sets local events at 30 days for failure or labelling defects, 10 days for death or serious deterioration and 48 hours for a serious public health threat. For foreign events it uses a different scale: a major safety issue must be reported no later than 3 calendar days, and a foreign withdrawal or suspension of registration within 24 hours. The unit matters as much as the number. A commercial organisation that thinks in working days will miss a calendar day deadline, and the 24-hour category leaves no room for an approval chain.

Insight 4: the MDA channel for combination products is email, not the portal.

Reports on the MDA side of a combination product do not go through MeDCReSt. The MPR form PART 1 and PART 2 must be sent to mpr@mda.gov.my. This is an operational trap because the portal is the default route for every conventional device, and a procedure written around the portal will produce a late report for the combination product category. Both channels belong in the same SOP, with the category decision recorded before the channel is chosen.

Insight 5: the fee sits outside the pure device bands.

A drug-containing device attracts a registration fee of RM5,000 with an application fee of RM750 under the Fifth Schedule, which differs from the pure device C and D bands. Budgeting by analogy with a conventional device therefore understates the cost. The fee position should be confirmed from the schedule at the planning stage, because it affects the commercial case as well as the filing.

Insight 6: the attribute split table decides everything downstream.

The single most useful artefact in a combination product project is an attribute split table built in the first week: every component, every claim and every potential event, each marked with the responsible agency. The table is what converts the lead agency principle from a concept into a decision record. Built early, it drives the filing route, the reporting channel and the timeline that applies; built late, it becomes a reconstruction exercise conducted under deadline pressure.

4. Practical recommendations

• Build the attribute split table in week one. Components, claims and foreseeable events, each with a named agency.
• File the ancillary dossier deliberately. Treat the supporting agency submission as a separate workstream with its own completeness check.
• Write both reporting channels into the SOP. MeDCReSt for conventional devices, the MPR form to mpr@mda.gov.my for combination products.
• Use calendar days for foreign events. Build the 3-day and 24-hour routes with named contacts and pre-approved templates.
• Pre-approve the 24-hour notification content. A withdrawal or suspension abroad cannot wait for a drafting cycle.
• Confirm the fee from the Fifth Schedule. Budget RM5,000 for registration and RM750 for the application, and verify against the current schedule before submission.
• Record the lead agency decision with reasons. Where the dominant aspect was arguable, document why the chosen agency was selected.

5. Verification checklist

• □ MDA Guideline for Drug-Medical Device and Medical Device-Drug Combination Products, fifth edition, on file
• □ Lead agency table and reporting timeline table extracted into the project file
• □ Attribute split table completed for every component, claim and foreseeable event
• □ MDR 2012 Fifth Schedule fee for drug-containing devices confirmed
• □ MDA Vigilance Unit page checked for the combination product email channel
• □ MPR form PART 1 and PART 2 prepared in advance
• □ Local and foreign timelines differentiated, including 3 calendar days and 24 hours

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Malaysia. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the MDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com